<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="70468">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01868841</url>
  </required_header>
  <id_info>
    <org_study_id>13-039</org_study_id>
    <nct_id>NCT01868841</nct_id>
  </id_info>
  <brief_title>123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging on a Small Field of View-High Efficiency Cardiac SPECT System</brief_title>
  <official_title>123-I mIBG (AdreView) Heart-to-Mediastinal (H/M) Ratio and SPECT Imaging</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Timothy M. Bateman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aspire Foundation</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate correlation of the H/M ratio of AdreView when
      derived from a large field of view Anger SPECT system and from a small field of view high
      sensitivity (CZT) SPECT system.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">June 2014</completion_date>
  <primary_completion_date type="Anticipated">June 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Relationship of H/M ratios obtained on LFOV and SFOV-HE systems</measure>
    <time_frame>3 months post-enrollment close</time_frame>
    <safety_issue>No</safety_issue>
    <description>H/M ratios as described will be calculated for the LFOV, and SFOV-HE data sets to determine the correlation between the two measurements.  The r value, slope and intercept of this correlation will constitute the primary endpoint of this study. Specifically, we will establish the r value, slope and intercept for: LFOV-Planar vs LFOV-TOMO, LFOV-Planar vs SFOV-HE-TOMO, LFOV-TOMO vs SFOV-HE-TOMO.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Image Quality</measure>
    <time_frame>3 month post-enrollment close</time_frame>
    <safety_issue>No</safety_issue>
    <description>We will investigate differences between the measurements in the SFOV-HE using the forward projections of the tomographic data and tomographic measurements of the H/M as other methods of establishing the correlation between tomographic and planar measurement of mIBG uptake.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Heart Failure</condition>
  <condition>Cardiomyopathy</condition>
  <arm_group>
    <arm_group_label>Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SPECT imaging of 10 millicurie of Adreview</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>SPECT imaging of 10 millicurie of Adreview</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>AdreView</intervention_name>
    <description>10 millicurie of AdreView (123I-mIBG)</description>
    <arm_group_label>Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging</arm_group_label>
    <arm_group_label>AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Single Photon Emission Computed Tomography</intervention_name>
    <arm_group_label>Adreview LFOV SPECT Imaging followed by SFOV-HE Imaging</arm_group_label>
    <arm_group_label>AdreView SFOV-HE SPECT Imaging followed by LFOV Imaging</arm_group_label>
    <other_name>SPECT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  New York Heart Association Class II or III Heart Failure

          -  Left ventricular ejection fraction less than or equal to 35%

        Exclusion Criteria:

          -  Uncompensated heart failure

          -  Recent hospitalization within 30 days of cardiac related indications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy M Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aspire Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Staci A Courter, MA</last_name>
    <phone>816-531-2842</phone>
    <phone_ext>107</phone_ext>
    <email>scourter@cvit.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>James A Case, PhD</last_name>
    <phone>816-531-2842</phone>
    <phone_ext>101</phone_ext>
    <email>jcase@cvit.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardiovascular Imaging Technologies</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James A Case, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy M Bateman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 20, 2013</lastchanged_date>
  <firstreceived_date>May 14, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Aspire Foundation</investigator_affiliation>
    <investigator_full_name>Timothy M. Bateman</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>123I-mIBG</keyword>
  <keyword>AdreView</keyword>
  <keyword>SPECT</keyword>
  <keyword>Heart to Mediastinal Ratio</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
